



Chemours Announces Board Leadership Appointments: Mary Cranston Named Chair, Alister Cowan Named Lead Independent Director

September 3, 2025

WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 3, 2025-- The Chemours Company ("Chemours") today announced that its Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan to the role of Lead Independent Director, effective September 2, 2025. These appointments follow the departure of Dawn Farrell, who has accepted a position with the Canadian government as the Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act.

"While Dawn's departure is a loss for Chemours, it is also a moment of pride. Dawn's appointment is a testament to her exceptional leadership and deep commitment to public service," said Denise Dignam, President and CEO of Chemours. "I welcome the leadership of Mary and Alister in their new roles—continuing the partnership we have established. I am confident that together, we will ensure the successful execution of our Pathway to Thrive strategy."

Cranston, a director since 2015, led Chemours' multi-year Board refresh, bringing in high-impact leaders aligned with the company's strategic priorities. She brings decades of governance leadership experience from serving on boards of global public companies, including Visa, McAfee, and TPG, and was the Chair and CEO of Pillsbury Winthrop Shaw Pittman LLC.

"It's a privilege to serve as the Board Chair of Chemours," said Mary Cranston. "We've built a Board with the right mix of skills, independence, and industry insight to support the company's growth. In this new structure, I will manage the Board, set the agenda and drive its focus on strategy and shareholder value creation, and Alister will primarily focus on board activities related to overall financial performance and strengthening the balance sheet. I look forward to working closely with Alister and our fellow directors to support Denise and the management team as they execute our Pathway to Thrive strategy."

Cowan, appointed to the Board in 2023, is a seasoned financial executive with over 30 years of experience, including 15 years as a public company CFO. He brings deep expertise in capital markets, risk management, and corporate development, having served as CFO of Suncor Energy and Husky Energy. Cowan chairs the Audit, Risk, and Finance Committee, positioning him to complement Chair Cranston's board leadership with his strong financial background.

"I'm honored to take on this role at such an exciting time for the company and to work with this strong management team and deeply committed board," said Alister Cowan. "I look forward to this expanded leadership role reinforcing the Board's work as we advance our Pathway to Thrive strategy and deliver long-term value for our shareholders."

About The Chemours Company

The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses—Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials—we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,000 employees and 28 manufacturing sites and serves approximately 2,500 customers in approximately 110 countries. For more information, visit chemours.com or follow us on [LinkedIn](https://www.linkedin.com/company/chemours).

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the advancement of our growth strategy and the impact of individual expertise on the company's strategy and performance, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, have affected or may affect our business and operations and may or may not continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that

Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250903473320/en/): <https://www.businesswire.com/news/home/20250903473320/en/>

INVESTORS

Brandon Ontjes

Vice President, Head of Strategy & Investor Relations

+1.302.773.3300

investor@chemours.com

NEWS MEDIA

Cassie Olszewski

Media Relations & Reputation Leader

+1.302.219.7140

media@chemours.com

Source: The Chemours Company